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Abstract Muscle atrophy is a process of muscle wast-
ing induced under a series of catabolic stress conditions,
such as denervation, disuse, cancer cachexia, heart
and renal failure, AIDS, and aging. Neuromuscular
junctions (NMJs), the synapses between motor neu-
rons and muscle fibers undergo major changes in
atrophying muscles, ranging from mild morphological
alterations to complete disintegration. In this study,
we hypothesized that remodeling of NMJs and mus-
cle atrophy could be linked together. To test this, we
examined if a major atrophy-promoting E3 ubiquitin
ligase, MuRF1, is involved in the maintenance of
NMJs. Immunofluorescence revealed that MuRF1 is
highly enriched close to the NMJ. Affinity precipitation
and in vivo imaging showed that MuRF1 interacts in
endocytic structures with both, acetylcholine receptor,
the primary postsynaptic protein of the NMJ, as well
as with Bif-1, an autophagy- and endocytosis-
regulating factor. In vivo imaging, radio labeling,
and weighing approaches demonstrated that metabolic
destabilization of acetylcholine receptors and muscle
atrophy induced by denervation were significantly
rescued in MuRF1-KO animals. Notably, interaction
with Bif-1, and the rescue of AChR lifetime and
muscle atrophy were specific to MuRF1 but not
MuRF2. Our data demonstrate an involvement of
MuRF1 in membrane protein-turnover, including the
degradation of AChRs at the NMJ under atrophying
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Introduction
Progressive reduction of skeletal muscle mass and
contractility increasingly represents a major health
issue in the aging populations of developed
countries. Major causes for muscle wasting include
sedentary lifestyle, a series of diseases — such as
diabetes, cancer, AIDS, heart and renal failure —
and aging itself. Although muscle atrophy is usual-
ly considered as a primary disorder of the sarco-
mere, there are intimate connections between
innervation activity and atrophy: For example, de-
nervation (sciatic nerve lesion) is used in rodents to
induce atrophy experimentally (Bodine et al. 2001;
Cohen et al. 2009), and in the clinic therapeutic
blockade of the neuromuscular junction (NMJ) by
depolarizing agents is a risk factor for aging-related
atrophy in critical illness myopathy (Latronico et al.
2005a, b). Furthermore, NMJ gross morphology
significantly deteriorates in aging muscle resulting
in progressive fragmentation of synapses and partial
functional denervation (Tuffery 1971; Gutmann and
Hanzlikova 1976; Pestronk et al. 1980; Courtney
and Steinbach 1981; Valdez et al. 2010; Chen et al.
2012). Of note, genetically induced NMJ fragmen-
tation recapitulates major aspects of aging-related
atrophy, such as fiber type grouping, fiber size
heterogeneity, and fiber loss (Butikofer et al.
2011). Finally, typical atrophy treatments used in
clinics such as resistance training and metabolic
manipulations reverse the severe fragmentation of
aging NMJs (Andonian and Fahim, 1987, 1988;
Valdez et al. 2010). On the molecular level, both
denervation and NMJ blockade activate the so-
called atrogene gene program (Bodine et al.
2001; Lecker et al. 2004; Sandri et al. 2004). This
program includes, in particular, a family of E3
ubiquitin ligases that are considered as central
players in the degradation of muscle proteins
(Bodine et al. 2001; Lecker et al. 2004). Prompted
by this apparent convergence of mechanisms in
muscle atrophy and NMJ deformation we here
investigated the role of the classical muscle atro-
phy marker, MuRF1, in the maintenance of the
NMJ. Our data suggest that atrophy and functional
denervation are intimately connected and that they
are two aspects of the same adaptive chronic stress




The MuRF1−/− KO and MuRF2−/− KO lines
used here have been described previously (Witt
et al. 2008). Here, 10- to 14-week-old MuRF1
and MuRF1 KO mice were backcrossed for ten
generations on a C57BL/6 J background. Animals
were maintained in the local animal facilities. Use
and care of animals were as approved by German
authori t ies and according to nat ional law
(TierSchG §§7). Anaesthesia was administered
using either inhalation of Isoflurane (cp-pharma)
or intraperitoneal (i.p.) injection of Rompun
(Bayer) and Zoletil 100 (Laboratoires Virbac).
For hindlimb denervation, 5 mm of the sciatic
nerve were removed. Success of denervation was
checked in sacrificed mice at the end of each
experiment. For transfection of isolated mouse
models, we electroporated expression plasmids
essentially as previously described (Dona et al.
2003; Choi et al. 2012; Rudolf et al. 2012).
Immunofluorescence
For immunofluorescence, 15-μm-thick transversal
sections were prepared from snap-frozen extensor dig-
itorum longus muscles. Stainings used α-bungarotoxin
(BGT) fluorescently labeled with AlexaFluor 555
(BGT-AF555) to mark acetylcholine receptors
(AChRs) in NMJs. MuRF1 was detected with three
different antibodies as described previously with
polyclonal antibodies raised against the coiled-coil
domain of MuRF1 (Witt et al. 2008; IgY-type
avian antibody ‘avian anti-MuRF1’). In addition,
we used two rabbit polyclonal antibodies raised
against the RING H2 domain (’rabbit anti-RING
H2 MuRF1’ and ‘rabbit anti-phospho-RING H2
MuRF1’; for more details, see www.myomedics.
com). All stainings were done using standard pro-
tocols as previously described (Röder et al. 2010;
Choi et al. 2012).
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Protein interaction assays (yeast two-hybrid
and co-precipitations)
For yeast two-hybrid assays (Y2H), mating experi-
ments were performed essentially as described (Witt
et al. 2008). Y2H prey–bait interaction data were
further verified by co-immunoprecipitations (co-
IPs): for co-IP analysis, WT and MuRF1-KO mice
were starved for 24 h. Mice were then killed,
quadriceps muscles prepared, shock frozen in liquid
nitrogen, and then stored at −80 °C. Tissues were
then levigated under liquid nitrogen and homoge-
nized in 50 mM Tris/Cl pH 8.0, 150 mM NaCl,
1 % NP40 and 10 % Glycerol, 1 mM DTT includ-
ing 1× Protease- and Phosphatase-Inhibitor cocktails
(Roche). After incubation at 4 °C for 1 h, extracts
were centrifuged for 10 min at 4,000×g. Superna-
tants were aliquoted and frozen at −80 °C until use.
For co-IP of MuRF1 and Bif-1, we combined an
amount of extract corresponding to one fifth of a
quadriceps in a final volume of 1 ml lysis buffer
with 30 μg rabbit polyclonal anti-RING H2 MuRF1
antibody (Myomedics) and incubated with light
shaking at 4 °C over night. 30 μl of Protein A-
sepharose (Pierce) equilibrated in lysis buffer was
added and incubated for an additional hour at 4 °C.
Beads were collected by spinning 1 min at 4 °C
and washed three times with 1 ml of lysis buffer.
The final pellet was resuspended directly in SDS
loading buffer. Affinity co-precipitation of MuRF-1
with in vivo labeled AChRs and biotinylated BGT
from Invitrogen and NeutrAvidin agarose from
ThermoScientific was performed as described pre-
viously (Röder et al. 2008, 2010; Choi et al.
2012). For Western blotting, samples were run on
4–12 % BisTris-Gels (Invitrogen) and blotted onto
nitrocellulose membranes. Detection of MuRF1
was performed with anti-MuRF1 IgY-type antibod-
ies from chicken (Myomedics), coupled to anti
chicken-AP (Jackson). Bif-1 was detected with
α-Bif-1 (goat, Abcam 1343), α-goat-biotinylated
(Dako) and Streptavidin-AP (Pierce). Monoclonal
antibodies against AChR α-subunit (610989) and
α-actinin (A7811) were from BD Bioscience and
Sigma-Aldrich, respectively. Polyclonal antibody
against β1-adrenergic receptor (PA1-049) was from
Affinity Bioreagents. Secondary anti-mouse and
anti-rabbit antibodies coupled to HRP were from
Dako.
In vivo transfection, imaging and AChR lifetime
determination
Expression of heterologous fusion proteins employed
MuRF1 and Bif-1 both fused to EGFP in pEGFP-C1
(for MuRF1-eGFP-C1 fusion constructs, see McElhinny
et al. 2002). Similarly, Bif-1 was inserted into
pEGFP-C1. Transfection of expression constructs into
tibialis anterior muscles was done as previously de-
scribed (Dona et al. 2003; Röder et al. 2008). Ten
days later, mice were anaesthetized and transfected
muscles exposed and injected with BGT-AF647 as
described previously (Röder et al. 2008; Rudolf et al.
2012). Then, mice were transferred to the confocal
microscope (DMRE TCS SP2, Leica Microsystems).
GFP and BGT-AF647 fluorescence were excited us-
ing a KrAr laser (488 nm) and a HeNe laser
(633 nm), respectively. Emission was detected by a
63x/1.2NA HCX PL APO CS W CORR objective
(Leica Microsystems) (immersion medium, Visc-
Ophtal gel, Winzer-Pharma) using 500–550 and
650–750 nm bandpass settings for GFP and BGT-
AF647, respectively, in the SP2 unit. Microscopic
determination of AChR turnover was done as de-
scribed before (Röder et al. 2008, 2010; Choi et al.
2012). In brief, infrared fluorescent BGT-AF647 (first
injection, labels 'old receptor' pool) and red fluorescent
BGT-AF555 (second injection, labels 'new receptor'
pool) were sequentially injected at a temporal distance
of 10 days. After the second injection muscles were
examined in vivo with confocal microscopy. Determina-
tion of AChR lifetime was executed as recently described
(Strack et al. 2011; Choi et al. 2012) and used 125I-labeled
BGT (125I-BGT) from Perkin Elmer. 125I emission was
quantified using a liquid nitrogen-cooled GX-3018 ger-
manium semiconductor detector (Canberra) and an
electrically cooled GEM-FX5825P4-S germanium
semiconductor detector (Ortec).
Results
MuRF1 is highly enriched beneath the NMJ
In previous studies, MuRF1 was found to associate
with the giant myofibrillar protein titin within its M-
line integral segment (Centner et al. 2001; Mrosek et
al. 2007; Hirner et al. 2008). Another set of studies
using different antibodies localized MuRF1 epitopes
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in the soluble fraction in the cytoplasm (Cohen et al.
2009). However, because MuRF1 is part of a highly
conserved RING finger protein family, antibodies may
cross-react with the three known members of the
MuRF gene family. So far, nothing is known about a
possible role of MuRF1 in the area of the NMJ. To
address this issue we first investigated if MuRF1 is
expressed in the NMJ region using different antibodies
raised to MuRF1-specific epitopes. Muscle cross-
sections were co-stained with fluorescent BGT-
AF555, a marker of AChRs, and three different anti-
MuRF1 antibodies, which were raised either to the
coiled-coil or to the RING H2 domain of the molecule
(for more details, see www.myomedics.com). Notably,
sections from wild-type muscles displayed for all three
anti-MuRF1 antibodies a high labeling intensity in
close proximity of the NMJs and much weaker signals
in the sarcomeric regions (Fig. 1). Conversely, sec-
tions from MuRF1-KO animals were almost com-
pletely devoid of immunofluorescence signals (Fig. 1).
This shows that MuRF1 accumulates in the endplate
areas of skeletal muscle fibers suggesting a specific role
of this protein in synapse-related processes. This local-
ization was consistently detected with the three different
types of anti-MuRF1 antibodies. To further address the
possibility of cross-reactivity with the other highly re-
lated RING-finger proteins MuRF2 or MuRF3, we also
analyzed the targeting of MuRF1-GFP fusion proteins
in vivo in transgenic muscles (see section on MuRF1-
GFPs; Fig. 2b and c). These experiments confirmed the
targeting of MuRF1 to the NMJ.
MuRF1 co-precipitates with AChRs
Prompted by the unexpectedly strong subsynaptic en-
richment of MuRF1 we then tested the association of
the E3 ligase with synaptic components. The major
postsynaptic protein of the NMJ is the AChR, which is
first exposed at the postsynaptic membrane and
then eventually undergoes cycles of endocytosis
and lysosomal degradation or recycling, in an activity-
dependent manner (Engel et al. 1977; Stanley and
Drachman 1981 Fumagalli et al. 1982; Akaaboune et
al. 1999; Bruneau et al. 2005). To screen for a poten-
tial interaction between MuRF1 and AChR we first
used a previously established assay based on the α-
bungarotoxin- (BGT) mediated affinity precipitation
of cell surface-exposed and endocytosed AChRs in
vivo (Röder et al. 2008). The 8-kDa snake venom,
BGT, is not membrane-permeable and binds to the
extracellular part of AChRs with extremely high speci-
ficity and in an essentially irreversible manner
(Changeux et al. 1970; Akaaboune et al. 1999). We
injected BGT-biotin into live gastrocnemius muscle,
allowing it to first bind to surface-exposed AChRs and
then to follow the AChRs during endocytosis and
Fig. 1 Endogenous MuRF1 is highly enriched in close prox-
imity to the NMJ. EDL muscles of WT and MuRF1-KO animals
were sectioned transversally and co-stained with the AChR
marker, BGT-AF555, and with three different anti-MuRF1 anti-
bodies, i.e., IgY-type from chicken against the MuRF1 coiled-
coil domain (a); IgG-type rabbit polyclonal antibodies directed
to the MuRF1 RING H2 domain (b, c). Fluorescence distribu-
tion was then determined using confocal microscopy. Pictures
show single optical sections of fluorescence signals of BGT-
AF555 (red) and anti-MuRF1 (green) of WT and MuRF1-KO
muscles, as indicated. Right panels depict high power views of
the boxed areas of the images on the left. Scale bars represent
50 μm
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recycling. Few hours later, muscles were harvested and
lysates prepared. BGT-biotin-bound AChRs were then
precipitated using standard protocols and lysates and
affinity precipitates analyzed by SDS-PAGE and
Western blots (Fig. 2a). This showed a robust precipita-
tion of AChRs and of the AChR-interacting protein, α-
actinin. While β1-adrenergic receptor, serving as a
negative control, did not precipitate, MuRF1 was al-
ways present in the sediments, although it was found
there in varying amounts. Figure 2a shows a represen-
tative experiment, but stronger MuRF1 bands in the
precipitate were also observed. Furthermore, control
preparations run without BGT-biotin injection were all
negative, hence strongly suggesting an interaction be-
tween MuRF1 and AChR.
MuRF1-GFP colocalizes with endocytic AChRs
Next, to investigate if the in vitro biochemical inter-
action between AChRs and MuRF1 relates to their
localization in vivo, we transfected MuRF1-GFP fu-
sion constructs into live tibialis anterior muscles. Ten
days after transfection, NMJs were labeled with fluo-
rescent BGT-AF647 and about an hour later muscles
were imaged in situ at the confocal microscope. In
general, MuRF1-GFP accumulated in the immediate
vicinity of the NMJs in small, punctuated structures
(Fig. 2b). Notably, nearly all of these structures co-
localized with puncta positive for endocytic AChRs
(Fig. 2b–c, white arrowheads in c). In a few cases,
MuRF1-GFP and BGT-AF647 signals were not per-
fectly overlapping but very close to each other
(Fig. 2c, red arrowhead). These results corroborate
an interaction of MuRF1 with AChR and indicate
that this interaction occurs mainly on carriers con-
taining AChRs in an endocytic, recycling or lysosomal
compartment.
MuRF1 does not affect AChR stability
under non-challenged basal conditions
Given the potential interaction between MuRF1 and
AChR on one hand, and the well-established roles of
ubiquitination on lysosomal targeting of membrane
receptors (Haglund and Dikic 2012) and the mainte-
nance of the NMJ (Lu et al. 2007) on the other hand,
we then studied if MuRF1 has a functional impact on
AChR turnover. First, we employed a previously
established in vivo imaging approach to study NMJ
morphology and AChR stability in MuRF1-KO mice
(Röder et al. 2008, 2010). In this assay, sequential
pulse labeling of AChR pools with differentially col-
ored BGT species indicates the intensity of AChR
turnover. A first injection indelibly marks 'old recep-
tors' with infrared fluorescent BGT-AlexaFluor647.
Ten days later a second application of BGT, tagged
Fig. 2 MuRF1 interacts with AChR on endo/lysosomal car-
riers. a BGT-biotin or solvent was injected into gastrocnemius
muscles. Five hours later, muscles were collected and lysates
prepared. From these, BGT-biotin-bound AChR and its interac-
tion partners were affinity-precipitated with neutravidin beads.
Panels show Western blot bands of lysates and affinity precip-
itates (AP) upon exposure to antibodies against AChRα,
MuRF1, α-actinin (positive control), or β1-adrenergic receptor
(β1-AR, negative control), as indicated. b–c Tibialis anterior
muscles were transfected with MuRF1-GFP. Ten days later,
muscles were injected with the fluorescent AChR marker,
BGT-AF647, and then monitored with in vivo confocal imag-
ing. After acquisition, all images were electronically contrasted
to highlight the weak endocytic AChR signals. In overlay pic-
tures, AChR and GFP signals appear red and green, respective-
ly. Colocalization of AChR and GFP signals is depicted in
yellow. b Median filtered single optical planes of fluorescence
signals. Scale bar represents 20 μm. c Panels depict high power
views of the boxed regions shown in b. White and red arrow-
heads indicate colocalizing and partially overlapping signals,
respectively, in endocytic carriers
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with red fluorescent AlexaFluor555, stains 'new
receptors' that were not present during the BGT-
AlexaFluor647 injection. Under normal conditions with
this procedure, most AChRs will carry the ‘old receptor’
stamp (BGT-AF647; green color in Fig. 3a–b) and only
very few show the ‘new receptor’ label (BGT-AF555;
red color in Fig. 3a–b). Interestingly, using this ap-
proach, both, wild-type (Fig. 3a; WT) and MuRF1-KO
muscles (Fig. 3b) displayed completely normal NMJ
morphology and apparent AChR turnover, suggesting
that MuRF1 does not influence AChR stability under
normal trophic conditions.
Under atrophic conditions AChR lifetime reduction
is partially rescued in MuRF1-KO animals
To further explore the involvement of MuRF1 in
AChR stability, we used a recently developed AChR
radio-labeling assay (Strack et al. 2011), where
AChRs are pulse-labeled with radioactive 125I-BGT
and 125I emission is then followed over 4 weeks. Ap-
plying this procedure to wild-type and MuRF1-KO
animals confirmed the in vivo-imaging result that un-
der normal trophic conditions MuRF1 plays no role in
AChR lifetime regulation (Fig. 3c–d, solid lines).
Since MuRF1 has been postulated to function as an
atrogene, i.e., as being activated under atrophic con-
ditions and to promote sarcomeric loss, we then
moved to an atrophy-inducing condition, in this case
denervation. Therefore, muscles were surgically de-
nervated at the level of the sciatic nerve 5 days before
the 125I-BGT pulse. Denervation led to a marked re-
duction in the half-life of AChRs and it did so in both,
wild-type as well as MuRF1-KO animals (Fig. 3c–d,
dashed lines). However, the AChR lifetime reduction
was significantly smaller in MuRF1-KO (Fig. 3c–d).
This shows that MuRF1 plays a pivotal role in activity-
dependent AChR turnover.
AChR stabilization under denervation-induced
atrophy is mediated by MuRF1 but not MuRF2
Previous studies have revealed a cooperative function of
MuRF1 andMuRF2 for maintaining muscle mass under
normal conditions (Witt et al. 2008). To find out if such
cooperation is also active upon catabolic stimulation, we
first determined muscle mass following denervation in
wild-type (WT) andMuRF1- or MuRF2-deficient mice.
Although denervation induced significant atrophy in all
three strains, muscles lacking MuRF1 were least affect-
ed and lost only about 30 % of their wet weight within
2 weeks (Fig. 4a). Conversely, muscles from MuRF2-
KO animals were indistinguishable from WT and lost
more than 50 % of wet weight (Fig. 4a). This shows that
MuRF1 is a major determinant of muscle catabolism,
while MuRF2 plays apparently no role in this process.
The observation of a MuRF1-specific regulation of
muscle atrophy upon denervation prompted us to inves-
tigate AChR stability in mice lacking MuRF2. Thus, we
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employed the radioiodine assay to determine AChR
lifetimes in MuRF1/2-double KO. Notably, these ani-
mals did not exhibit any enhancement of AChR stability
upon denervation as compared toMuRF1-KO (Fig. 4b).
Therefore, the partial rescue of AChR lifetime upon
denervation was MuRF1-specific and did not involve
MuRF2. These data further consolidate a primary func-
tion of MuRF1 in muscle catabolism.
Endophilin B1/Bif-1 interacts with MuRF1
in an isoform-specific manner
The finding of a MuRF1-exclusive role in muscle ca-
tabolism and its apparent involvement in AChR turn-
over led us to hypothesize that MuRF1 may act in the
regulation of endo/lysosomal trafficking. To investigate
this further, we re-surveyed prey clones from a previ-
ously published yeast-two-hybrid screen (Witt et al.
2008) for potential links to endo/lysosomal trafficking.
As a possible candidate, we identified a prey clone
coding for endophilin B1 alias Bif-1 (Bax-interacting
factor-1). Endophilin B1/Bif-1 was originally found to
orchestrate autophagy, mitochondrial morphology, and
apoptosis (Takahashi et al. 2009). A more recent study
identified this protein as crucial for the metabolic turn-
over of nerve growth factor receptor, TrkA (Wan et al.
2008; Cheung and Ip 2009). Notably, mating experi-
ments demonstrated that Bif-1 interacts with MuRF1,
but not withMuRF2 (Fig. 5a). To further consolidate the
interaction between Bif-1 andMuRF1we performed co-
IP. Lysates were prepared from quadriceps muscles, and
MuRF1 was precipitated using a rabbit polyclonal anti-
serum raised to the MuRF1 RING H2 domain. Western
blot showed a Bif-1-positive band in the precipitate at
44 kDa, which was absent in MuRF1-KO preparations
(Fig. 5b). Together, these data show that Bif-1 is a novel
interaction partner of MuRF1 and that within the
MuRF1, 2, 3 family this interaction is specific for the
MuRF1 isoform.
Fig. 4 MuRF1 but not MuRF2 regulates skeletal trophicity and
innervation. aMuscle masses of whole quadriceps muscles were
monitored 14 days after denervation in MuRF1- and MuRF2-
KO mice. Inactivation of MuRF1 but not MuRF2 protects
partially from muscle mass loss consistent with earlier data.
Columns show mean±SEM (n07) *p<0.001 according to
Welch test. bMuRF2 inactivation does not alter AChR stability.
Five days after sciatic denervation, AChRs in tibialis anterior
muscles were pulse-labeled with 125I-BGT. 125I emission was
monitored at indicated intervals during the next 4 weeks and
normalized to the values measured 24 h after pulse labeling.
Symbols show measured values (mean ± SEM, n02 for
MuRF1/2-dKO). Lines depict two-term exponential fits, WT
and MuRF1-KO fits, see Fig. 3b
Fig. 3 Metabolic destabilization of AChR upon denervation is
partially rescued in MuRF-1KO animals. a Tibialis anterior
muscles of wild-type (WT) and b MuRF1-KO animals were
injected with infrared fluorescent BGT-AF647 to label AChRs
present at that time point ('old receptors'). Ten days later, red
fluorescent BGT-AF555 was injected to mark 'new receptors'
and then muscles were imaged with confocal microscopy. Panels
showmaximum-z projections of 'old receptors' and 'new receptors'
in green and red, respectively. Note, that all NMJs displayed
hardly any 'new receptor' signals. Left legs of WT and MuRF1-
KO animals were denervated, right legs served as innervated
controls (c) or were left untreated and innervated controls were
from separate animals (d). Five days later, AChRs in tibialis
anterior muscles of all legs were pulse-labeled with 125I-BGT.
Then, 125I emission was monitored at indicated intervals during
the next 4 weeks and normalized to the values measured 24 h after
pulse labeling. Symbols show measured values (mean±SEM, c:
n03 forWTand n04 for MuRF1-KO, d: n04 for both denervated
WT and denervated MuRF1-KO muscles and n05 for both inner-
vatedWTand innervated MuRF1-KO muscles). Lines depict two-
term exponential fits. *p<0.05
AGE (2013) 35:1663–1674 1669
Bif-1-GFP is enriched at the NMJ and colocalizes
with endocytic AChRs
Finally, we asked if Bif-1 could potentially mediate
the linkage of MuRF1 to the endo/lysosomal compart-
ment containing AChRs. To address this, we studied
the subcellular distribution of Bif-1 by expressing a
Bif-1-GFP fusion protein in live mouse tibialis anteri-
or muscle. NMJs were labeled with fluorescent BGT-
AF647 and fluorescence signals were then monitored
with in vivo imaging. This showed an interesting
distribution pattern of Bif-1-GFP (Fig. 5c): While a
minor portion of the GFP fluorescence was observed
in a striated pattern of the sarcomeric region, large
amounts of fusion protein were detected in the NMJ
region. Additionally, punctuate structures were found,
resembling those of MuRF1-GFP in number and lo-
calization next to the NMJ. Interestingly, these puncta
again largely colocalized with or mounted carriers
containing endocytosed AChRs (Fig. 5c, white or red
arrowheads, respectively). This suggests that Bif-1
might serve a similar function for AChR turnover as
for TrkA.
Discussion
Catabolic stress conditions induce a conserved set of
transcripts during muscle wasting (referred to as
atrogenes) thus holding promise to possibly attenuate
this genetic reprogramming (Bodine et al. 2001).
These atrogenes include several ubiquitin E3 ligases,
enzymes that initiate the degradation of their target
proteins by catalyzing the addition of ubiquitin to
exposed lysine residues in their respective targets in
conjunction with non-rate limiting E1 and E2 ligase
activities. Thereby, induction of atrophy-associated
E3 ligases is thought to induce muscle atrophy
by the degradation of sarcomeric muscle proteins,
including in particular myosin, actin, and troponin
I (Bodine et al. 2001; Glass 2005, 2010; Adams et
al. 2008).
Fig. 5 Bif-1 interacts with MuRF1 and targets to the NMJ and
endo/lysosomal carriers containing AChR. a Bif-1 was found to
interact withMuRF1 in a previous yeast two-hybrid screen (Witt et
al. 2008). Follow-up by mating confirms this interaction and
moreover suggests that this interaction is specific for MuRF1 in
the MuRF protein RING finger family, since mating with MuRF2
did not yield β-galactosidase reporter activity (blue). b MuRF1
and Bif-1 form a complex in muscle extracts as indicated by
pulldown: MuRF1 and its associated binding proteins were pre-
cipitated with a MuRF1 specific antibody from soluble TA
extracts. In WT muscle extracts, MuRF1 and Bif-1 immunopos-
itive signals were detected with specific antibodies in the pull-
down at 40 and 44 kDa, respectively. Both signals were absent in
precipitates from MuRF1-KO muscle. c Tibialis anterior muscles
were transfected with Bif-1-GFP. Ten days later, muscles were
injected with the fluorescent AChRmarker, BGT-AF647, and then
monitored with in vivo confocal imaging. Left panels show medi-
an filtered single optical planes of fluorescence signals. Right
panels depict high power views of the boxed regions in left panels.
After acquisition, all images were electronically contrasted to
highlight the weak endocytic AChR signals. In overlay pictures,
AChR and GFP signals appear red and green, respectively. Coloc-
alization of AChR and GFP signals are shown in yellow. Scale bar
represents 20 μm
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Sarcomeric and NMJ remodeling are co-regulated
by MuRF1
Here, we have tested the hypothesis that during mus-
cle atrophy, E3 ligase-driven wasting of sarcomeres
and NMJ-driven remodeling could be linked together:
Recent studies suggest an important involvement of
the NMJ, since genetic subversion of NMJ stability
leads to major signs of aging-related atrophy, includ-
ing fiber type grouping, fiber size heterogeneity, and
fiber loss (Butikofer et al. 2011). Therefore, functional
muscle fiber denervation is a major reason for aging-
related atrophy (Rowan et al. 2012). Furthermore, the
finding of NMJ denervation without motoneuron loss
in aging mice shows that, at least partially, muscle-
specific processes can lead to functional denervation
in aging-related atrophy (Chai et al. 2011). Because
Rowan et al. (2012) found that protein expression of
the E3 ligase MuRF1 (an atrogene that has been ex-
tensively studied in sarcomeric muscle protein degra-
dation) was highest in denervated muscle fibers, we
concentrated here on the role of MuRF1 in the NMJ.
Consistent with our hypothesis that E3 ligases such as
MuRF1 may link together sarcomeric and NMJ
remodeling, we found that MuRF1 was highly
enriched in the NMJ region: MuRF1 immunostaining
obtained with three distinct anti-MuRF1 antibodies
was much stronger in the NMJ regions than in the rest
of the muscle fibers (Fig. 1). This raises the possibility
of a specific yet undiscovered function of MuRF1 at
the synapse.
MuRF1 plays a role in NMJ control by regulating
AChR lifetime
Given the presence of MuRF1 in the NMJ we tested
then if MuRF1 might participate in synaptic function-
ing of the major player in the postsynaptic portion of
the NMJ, i.e., the AChR. This ligand-gated pentameric
ion channel (Karlin 2002) transduces motorneuronal
activity into skeletal muscle activity and thus mediates
any kind of voluntary muscle contraction (Martyn et
al. 2009). Normally, AChR occurs at a quasi-crystalline
density of roughly 10,000 receptors per square
micron on the postsynaptic membrane (Fambrough
1979; Sanes and Lichtman 2001) and mutations of
the receptor, autoimmune responses against it, or
factors that reduce its amount are causative for severe
muscle weakness and diseases like myasthenia
gravis or congenital myasthenic syndromes (Engel et
al. 1977; Ohno and Engel 2002; Müller et al. 2007;
Palace and Beeson 2008). Co-IPs suggested that
MuRF1 could interact directly with AChR (Fig. 2).
Importantly, we also found that MuRF1 controls the
metabolic lifetime of AChRs under atrophying condi-
tions (Fig. 3). Given that AChR lifetime is known to
vary with AChR transcriptional activity in denervated
muscles (Yampolsky et al. 2010b) and that MuRF1 can
also be involved in the regulation of protein biosynthesis
(Witt et al. 2008), further studies are required to deter-
mine putative contributions of MuRF1 to the biogenesis
of AChRs. Our data imply that MuRF1 fulfills at least
one more, completely novel function, i.e., the regulation
of the skeletal muscle innervation status.
MuRF1 likely acts on regulating endo/lysosomal
progression of AChR
Mechanistically, the regulation of the metabolic stability
of the AChR is tightly coupled to its activity (Levitt et al.
1980; Loring and Salpeter 1980; Levitt and Salpeter
1981; Stanley and Drachman 1981, 1983; Shyng et al.
1991; Strack et al. 2011), and this largely involves
vesicular transport processes (Fumagalli et al. 1982;
Akaaboune et al. 1999). Indeed, like any other typical
transmembrane protein, newly generated AChRs reach
the postsynapse in exocytic carriers (Marchand et al.
2000, 2002; Marchand and Cartaud 2002). Subsequent-
ly, AChRs get endocytosed (Fumagalli et al. 1982;
Akaaboune et al. 1999) and either degraded in
lysosomes (Clementi et al. 1983; Kumari et al.
2008; Valkova et al. 2011) or recycled (Akaaboune
et al. 1999; Bruneau et al. 2005); this decision is clearly
muscle activity-dependent and the recycling process
involves the cooperative function of myosin Va, protein
kinase A, and the anchor protein, rapsyn (Röder et al.
2008, 2010; Yampolsky et al. 2010a; Choi et al. 2012).
For many other receptor molecules a conserved cascade
of small Rab-GTPases is instrumental in the progression
from endosomes to recycling endosomes or lysosomes
(Huotari and Helenius 2011). In particular, the exchange
of Rab5 with Rab7 appears to be critical for the endo/
lysosomal maturation. Much less is known about the
AChR degradation route, and our data implicateMuRF1
here. Consistent with this hypothesis, MuRF1 is down-
regulated during physical activity (Adams et al. 2008),
and, conversely, it is strongly upregulated during phys-
ical inactivity. Thus, the rapsyn- and protein kinase A
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activity-promoted stabilization on the one hand and the
inactivity-promoted MuRF1-dependent destabilization
of AChRs on the other hand are likely to be physiolog-
ically antagonistic regulatory processes. How MuRF1
exerts this regulatory function mechanistically is un-
clear, but it is likely that it involves further factors. In
this study we identified one such candidate molecule,
Bif-1 alias endophilin B1. Recently, this liposome tubu-
lation factor was found to localize on early endosomes
and to regulate the endo/lysosomal progression of the
nerve growth factor receptor, TrkA (Wan et al. 2008;
Cheung and Ip 2009). Thus, we were excited to find that
MuRF1 interacts with both AChR (Fig. 2) and Bif-1
(Fig. 5). Furthermore, MuRF1 and Bif-1 both colocalize
with endocytic AChRs in close proximity to the NMJ
(Figs. 2 and 5). These observations strongly suggest that
Bif-1 might play a similar role in endo/lysosomal pro-
gression for AChRs as for TrkA.
Outlook — MuRF1-specific activation signals
needed?
Notably, the determination of AChR lifetime kinetics
of MuRF1-KO animals under normal and atrophic
(denervation) regimes demonstrates that MuRF1 plays
a pivotal role in AChR degradation only during atro-
phy but not under standard trophic conditions (Fig. 3):
a significantly reduced AChR destabilization develops
only upon denervation. This observation is consistent
with the finding that overexpression of MuRF1 alone
without additional signals is not sufficient to trigger
muscle wasting (Hirner et al. 2008), raising the possi-
bility that atrogene function(s) of MuRF1 may require
specific atrophic stimuli for activation. In this context,
we speculate that the sarcomere-associated form of
MuRF1 observed in the M-line after overexpression
in healthy non-challenged myocytes (McElhinny et al.
2002; Hirner et al. 2008) represents a titin-based com-
plex that still requires an activation signal for the
translocation of MuRF1 into the cytoplasm and/or
the NMJ. Finally, our studies on AChR lifetime regu-
lation demonstrate a specific role for MuRF1, since,
first, inactivation of MuRF2 alone is not sufficient to
attenuate wasting (Fig. 4a), second, AChR lifetime
kinetics in MuRF1,2-double-KO animals were identi-
cal to MuRF1-single-KO animals (Fig. 4b), and, third,
the interaction with Bif-1 was specific for MuRF1
within the MuRF family (Fig. 5). Taken together, our
data implicate MuRF1 as a key molecular regulator in
stimulated atrophy processes that cannot be compen-
sated for by MuRF2 or MuRF3. Future studies will
need to clarify if specific factors can activate MuRF1,
and how activated MuRF1 and Bif-1 may cooperate
during their joint functioning on sarcomeric and NMJ
remodeling.
Acknowledgments The authors thank the animal facilities for
their excellent support. We gratefully acknowledge the financial
support by the DFG to SL and RR.
Open Access This article is distributed under the terms of the
Creative Commons Attribution License which permits any use,
distribution, and reproduction in any medium, provided the
original author(s) and the source are credited.
References
Adams V, Mangner N, Gasch A, Krohne C, Gielen S, Hirner S,
Thierse HJ, Witt CC, Linke A, Schuler G, Labeit S (2008)
Induction of MuRF1 is essential for TNF-alpha-induced
loss of muscle function in mice. J Mol Biol 384:48–59
Akaaboune M, Culican SM, Turney SG, Lichtman JW (1999)
Rapid and reversible effects of activity on acetylcholine
receptor density at the neuromuscular junction in vivo.
Science 286:503–507
Andonian MH, Fahim MA (1987) Effects of endurance exercise
on the morphology of mouse neuromuscular junctions
during ageing. J Neurocytol 16:589–599
Andonian MH, Fahim MA (1988) Endurance exercise alters the
morphology of fast- and slow-twitch rat neuromuscular
junctions. Int J Sports Med 9:218–223
Bodine SC, Latres E, Baumhueter S, Lai VK, Nunez L, Clarke
BA, Poueymirou WT, Panaro FJ, Na E, Dharmarajan K,
Pan ZQ, Valenzuela DM, DeChiara TM, Stitt TN,
Yancopoulos GD, Glass DJ (2001) Identification of ubiquitin
ligases required for skeletal muscle atrophy. Science
294:1704–1708
Bruneau E, Sutter D, Hume RI, Akaaboune M (2005) Identifi-
cation of nicotinic acetylcholine receptor recycling and its
role in maintaining receptor density at the neuromuscular
junction in vivo. J Neurosci 25:9949–9959
Butikofer L, Zurlinden A, Bolliger MF, Kunz B, Sonderegger P
(2011) Destabilization of the neuromuscular junction by
proteolytic cleavage of agrin results in precocious sarcope-
nia. FASEB J 25:4378–4393
Centner T, Yano J, Kimura E, McElhinny AS, Pelin K, Witt CC,
Bang ML, Trombitas K, Granzier H, Gregorio CC, Sorimachi
H, Labeit S (2001) Identification ofmuscle specific ring finger
proteins as potential regulators of the titin kinase domain. J
Mol Biol 306:717–726
Chai RJ, Vukovic J, Dunlop S, Grounds MD, Shavlakadze T
(2011) Striking denervation of neuromuscular junctions
without lumbar motoneuron loss in geriatric mouse muscle.
PLoS One 6:e28090
1672 AGE (2013) 35:1663–1674
Changeux JP, Kasai M, Lee CY (1970) Use of a snake venom
toxin to characterize the cholinergic receptor protein. Proc
Natl Acad Sci U S A 67:1241–1247
Chen J, Mizushige T, Nishimune H (2012) Active zone density
is conserved during synaptic growth but impaired in aged
mice. J Comp Neurol 520:434–452
Cheung ZH, Ip NY (2009) Endophilin B1: guarding the gate to
destruction. Commun Integr Biol 2:130–132
Choi KR, Berrera M, Reischl M, Strack S, Albrizio M, Röder
IV, Wagner A, Petersen Y, Hafner M, Zaccolo M, Rudolf R
(2012) Rapsyn mediates subsynaptic anchoring of PKA
type I and stabilisation of acetylcholine receptor in vivo.
J Cell Sci 125:714–723
Clementi F, Sher E, Erroi A (1983) Acetylcholine receptor
degradation: study of mechanism of action of inhibitory
drugs. Eur J Cell Biol 29:274–280
Cohen S, Brault JJ, Gygi SP, Glass DJ, Valenzuela DM, Gartner
C, Latres E, Goldberg AL (2009) During muscle atrophy,
thick, but not thin, filament components are degraded by
MuRF1-dependent ubiquitylation. J Cell Biol 185:1083–
1095
Courtney J, Steinbach JH (1981) Age changes in neuromuscular
junction morphology and acetylcholine receptor distribu-
tion on rat skeletal muscle fibres. J Physiol 320:435–447
Dona M, Sandri M, Rossini K, Dell'Aica I, Podhorska-Okolow
M, Carraro U (2003) Functional in vivo gene transfer into
the myofibers of adult skeletal muscle. Biochem Biophys
Res Commun 312:1132–1138
Engel AG, Lindstrom JM, Lambert EH, Lennon VA (1977)
Ultrastructural localization of the acetylcholine receptor
in myasthenia gravis and in its experimental autoimmune
model. Neurology 27:307–315
Fambrough DM (1979) Control of acetylcholine receptors in
skeletal muscle. Physiol Rev 59:165–227
Fumagalli G, Engel AG, Lindstrom J (1982) Ultrastructural
aspects of acetylcholine receptor turnover at the normal
end-plate and in autoimmune myasthenia gravis. J Neuro-
pathol Exp Neurol 41:567–579
Glass DJ (2005) Skeletal muscle hypertrophy and atrophy sig-
naling pathways. Int J Biochem Cell Biol 37:1974–1984
Glass DJ (2010) Signaling pathways perturbing muscle mass.
Curr Opin Clin Nutr Metab Care 13:225–229
Gutmann E, Hanzlikova V (1976) Fast and slow motor units in
ageing. Gerontology 22:280–300
Haglund K, Dikic I (2012) The role of ubiquitylation in receptor
endocytosis and endosomal sorting. J Cell Sci 125:265–275
Hirner S, Krohne C, Schuster A, Hoffmann S, Witt S, Erber R,
Sticht C, Gasch A, Labeit S, Labeit D (2008) MuRF1-
dependent regulation of systemic carbohydrate metabolism
as revealed from transgenic mouse studies. J Mol Biol
379:666–677
Huotari J, Helenius A (2011) Endosome maturation. EMBO J
30:3481–3500
Karlin A (2002) Emerging structure of the nicotinic acetylcho-
line receptors. Nat Rev Neurosci 3:102–114
Kumari S, Borroni V, Chaudhry A, Chanda B, Massol R, Mayor
S, Barrantes FJ (2008) Nicotinic acetylcholine receptor is
internalized via a Rac-dependent, dynamin-independent
endocytic pathway. J Cell Biol 181:1179–1193
Latronico N, Peli E, Botteri M (2005a) Critical illness myopathy
and neuropathy. Curr Opin Crit Care 11:126–132
Latronico N, Shehu I, Seghelini E (2005b) Neuromuscular
sequelae of critical illness. Curr Opin Crit Care
11:381–390
Lecker SH, Jagoe RT, Gilbert A, Gomes M, Baracos V, Bailey J,
Price SR, Mitch WE, Goldberg AL (2004) Multiple types
of skeletal muscle atrophy involve a common program of
changes in gene expression. FASEB J 18:39–51
Levitt TA, Salpeter MM (1981) Denervated endplates have a
dual population of junctional acetylcholine receptors. Nature
291:239–241
Levitt TA, Loring RH, Salpeter MM (1980) Neuronal control of
acetylcholine receptor turnover rate at a vertebrate neuro-
muscular junction. Science 210:550–551
Loring RH, Salpeter MM (1980) Denervation increases turnover
rate of junctional acetylcholine receptors. Proc Natl Acad
Sci U S A 77:2293–2297
Lu Z, Je HS, Young P, Gross J, Lu B, Feng G (2007) Regulation
of synaptic growth and maturation by a synapse-associated
E3 ubiquitin ligase at the neuromuscular junction. J Cell
Biol 177:1077–1089
Marchand S, Cartaud J (2002) Targeted trafficking of neuro-
transmitter receptors to synaptic sites. Mol Neurobiol
26:117–135
Marchand S, Bignami F, Stetzkowski-Marden F, Cartaud J
(2000) The myristoylated protein rapsyn is cotargeted with
the nicotinic acetylcholine receptor to the postsynaptic
membrane via the exocytic pathway. J Neurosci 20:521–
528
Marchand S, Devillers-Thiery A, Pons S, Changeux JP, Cartaud
J (2002) Rapsyn escorts the nicotinic acetylcholine recep-
tor along the exocytic pathway via association with lipid
rafts. J Neurosci 22:8891–8901
Martyn JA, Fagerlund MJ, Eriksson LI (2009) Basic principles
of neuromuscular transmission. Anaesthesia 64(Suppl
1):1–9
McElhinny AS, Kakinuma K, Sorimachi H, Labeit S, Gregorio
CC (2002) Muscle-specific RING finger-1 interacts with
titin to regulate sarcomeric M-line and thick filament struc-
ture and may have nuclear functions via its interaction with
glucocorticoid modulatory element binding protein-1. J
Cell Biol 157:125–136
Mrosek M, Labeit D, Witt S, Heerklotz H, von Castelmur E,
Labeit S, Mayans O (2007) Molecular determinants for the
recruitment of the ubiquitin-ligase MuRF-1 onto M-line
titin. FASEB J 21:1383–1392
Müller JS, Mihaylova V, Abicht A, Lochmüller H (2007) Con-
genital myasthenic syndromes: spotlight on genetic defects of
neuromuscular transmission. Expert Rev Mol Med 9:1–20
Ohno K, Engel AG (2002) Congenital myasthenic syndromes:
genetic defects of the neuromuscular junction. Curr Neurol
Neurosci Rep 2:78–88
Palace J, Beeson D (2008) The congenital myasthenic syn-
dromes. J Neuroimmunol 201–202:2–5
Pestronk A, Drachman DB, Griffin JW (1980) Effects of aging
on nerve sprouting and regeneration. Exp Neurol 70:65–82
Röder IV, Petersen Y, Choi KR, Witzemann V, Hammer JA 3rd,
Rudolf R (2008) Role of Myosin va in the plasticity of the
vertebrate neuromuscular junction in vivo. PLoS One 3:
e3871
Röder IV, Choi KR, Reischl M, Petersen Y, Diefenbacher ME,
Zaccolo M, Pozzan T, Rudolf R (2010) Myosin Va
AGE (2013) 35:1663–1674 1673
cooperates with PKA RIalpha to mediate maintenance of the
endplate in vivo. Proc Natl Acad Sci U S A 107:2031–2036
Rowan SL, Rygiel K, Purves-Smith FM, Solbak NM, Turnbull
DM, Hepple RT (2012) Denervation causes fiber atrophy
and myosin heavy chain co-expression in senescent skele-
tal muscle. PLoS One 7:e29082
Rudolf R, Hafner M, Mongillo M (2012) Investigating second
messenger signaling in vivo. Methods Enzymol 505:363–382
Sandri M, Sandri C, Gilbert A, Skurk C, Calabria E, Picard A,
Walsh K, Schiaffino S, Lecker SH, Goldberg AL (2004)
Foxo transcription factors induce the atrophy-related ubiq-
uitin ligase atrogin-1 and cause skeletal muscle atrophy.
Cell 117:399–412
Sanes JR, Lichtman JW (2001) Induction, assembly, maturation
and maintenance of a postsynaptic apparatus. Nat Rev
Neurosci 2:791–805
Shyng SL, Xu R, Salpeter MM (1991) Cyclic AMP stabilizes
the degradation of original junctional acetylcholine recep-
tors in denervated muscle. Neuron 6:469–475
Stanley EF, Drachman DB (1981) Denervation accelerates the
degradation of junctional acetylcholine receptors. Exp
Neurol 73:390–396
Stanley EF, Drachman DB (1983) Rapid degradation of "new"
acetylcholine receptors at neuromuscular junctions. Science
222:67–69
Strack S, Petersen Y, Wagner A, Röder IV, Albrizio M, Reischl
M, Wacker IU, Wilhelm C, Rudolf R (2011) A novel
labeling approach identifies three stability levels of acetyl-
choline receptors in the mouse neuromuscular junction in
vivo. PLoS One 6:e20524
Takahashi Y, Meyerkord CL, Wang HG (2009) Bif-1/endophilin
B1: a candidate for crescent driving force in autophagy.
Cell Death Differ 16:947–955
Tuffery AR (1971) Growth and degeneration of motor end-plates
in normal cat hind limb muscles. J Anat 110:221–247
Valdez G, Tapia JC, Kang H, Clemenson GD Jr, Gage FH,
Lichtman JW, Sanes JR (2010) Attenuation of age-related
changes in mouse neuromuscular synapses by caloric restric-
tion and exercise. Proc Natl Acad Sci U S A 107:14863–
14868
Valkova C, Albrizio M, Röder IV, Schwake M, Betto R, Rudolf
R, Kaether C (2011) Sorting receptor Rer1 controls surface
expression of muscle acetylcholine receptors by ER reten-
tion of unassembled alpha-subunits. Proc Natl Acad Sci U
S A 108:621–625
Wan J, Cheung AY, Fu WY, Wu C, Zhang M, Mobley WC,
Cheung ZH, Ip NY (2008) Endophilin B1 as a novel
regulator of nerve growth factor/TrkA trafficking and neu-
rite outgrowth. J Neurosci 28:9002–9012
Witt CC, Witt SH, Lerche S, Labeit D, Back W, Labeit S (2008)
Cooperative control of striated muscle mass and metabo-
lism by MuRF1 and MuRF2. EMBO J 27:350–360
Yampolsky P, Pacifici PG, Lomb L, Giese G, Rudolf R, Röder
IV, Witzemann V (2010a) Time lapse in vivo visualization
of developmental stabilization of synaptic receptors at neu-
romuscular junctions. J Biol Chem 285:34589–34596
Yampolsky P, Pacifici PG, Witzemann V (2010b) Differen-
tial muscle-driven synaptic remodelin in the neuromus-
cular junction after denervation. Eur J Neurosci 31:646–
658
1674 AGE (2013) 35:1663–1674
